Preliminery Scientific Programme
by October 2024
Wednesday, 4 December 2024
08:00-09:45
Registration
09:45-10:00
Welcome, introduction and objectives
Ana Giménez-Arnau (Spain) | Torsten Zuberbier (Germany) | Emek Kocatürk (Germany) | Luis Ensina (Brazil)
Keynote lecture Session I: Pathophysiology Endotyping of CSU:
10:00-10:25
Chronic spontaneous urticaria: Update on pathophysiology
10:25-10:50
Non-IgE-mediators and neurogenic activation of mast cells
Oral Presentation Session I: Aetiopathogenesis of Urticaria, Differential Diagnosis, Comorbidities and diagnostic approaches
10:50-11:36
Oral Presentations
11:36-12:00
Coffee Break
EMBRN Session: The biology of mast cells and basophils and their role in health and disease
12:00-12:05
EMBRN Introduction
12:05-12:20
The Evolving Story of the Allergic Effector Unit
12:20-12:35
Mast cells and tissue infiltrating immune cells
12:35-12:50
Mast cells in the skin: enemies driving inflammation or defenders of integrity?
12:50-12:55
Summary
12:55-13:55
Symposium
13:55-14:25
Lunch Break
Keynote lecture Session II: Endotypes and Biomarkers of CU
14:25-14:50
Endotypes of CSU – What we know and what we don´t know
14:50-15:15
Biomarkers of CU clinical behavior and therapy response to available treatments
Oral Presentation Session II: Urticaria treatments, predictors of response and biomarkers in CU
15:15-16:02
Oral Presentations
14:49-14:58
OP.007 PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)
14:07-15:16
OP.009 Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)
14:58-15:07
OP.008 Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)
14:16-15:25
OP.010 In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)
16:02-16:35
Coffee Break
Poster Walks and Poster Session
16:35-17:35
Poster walks and poster session
In Recognition of the Great Person, Marcus Maurer.
17:35-18:35
The history of modern urticaria and a tribute to Marcus Maurer
Oral Presentation Session III: Urticaria treatments and predictors of response
16:20-16:40
What’s new?
16:40-17:25
Oral Presentations
17:49-17:58
OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)
17:58-18:07
OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)
18:07-18:16
OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)
18:16-18:25
OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)
18:25-18:34
OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)
18:34-18:43
OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)
18:43-18:52
OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)
18:35
Scientific Dinner
Thursday, 5 December 2024
07:15-08:30
Registration
08:30-08:35
Welcome and summary day 1
Ana Giménez-Arnau (Spain) | Torsten Zuberbier (Germany) |
Emek Kocatürk (Germany) | Luis Ensina (Brazil)
08:35-09:05
Pearls of UCARE / UCARE Pinnacles / UCARE Beacons / UCARE Jewels
09:05-09:38
Current UCARE Scientific Projects
09:38-09:56
Ucpcoming Projects
14:48-15:01
Importance of the complement test in patients with angioedema taking ACE inhibitor
Henriette Farkas (Hungary)
15:01-15:14
The use of anti-IgE therapy to define idiopathic non-histaminergic angioedema
Jason Fok (Australia)
15:14-15:27
Estrogen triggering non-hereditary Angioedema
Anete Grumach (Brazil)
15:27-15:40
ACARE projects and activities
Markus Magerl (Germany)
Oral Presentation Session III: Urticariological highlights
09:56-10:41
Oral Presentations
09:14-09:23
OP.020 Treatment with MRGPRX2 Antagonist EP262 Potently Inhibits Mast Cell Degranulation
Veena Viswanath (USA)
09:23-09:32
OP.021 Remibrutinib improves CSU in patients with low or high IgE
Michihiro Hide (Japan)
09:32-09:41
OP.022 Anti-IL-23 treatment in patients with omalizumab-refractory chronic spontaneous urticaria – a case series
Hanna Bonnekoh (Germany)
09:41-09:50
OP.023 Omalizumab drug survival for chronic urticaria – the DruSO-CU UCARE study
Reineke Soegiharto (The Netherlands)
09:50-09:59
OP.024 CRUSE – What the first 100 days have taught us
Sophia Neisinger (Germany)
10:41-11:10
Coffee Break
ACARE Session: Recurrent angioedema
11:10-11:20
Intro about ACARE and welcome
11:20-11:40
Predictive model to differentiate chronic histaminergic angioedema and chronic spontaneous urticaria with angioedema
11:40-12:00
Update on ACARE projects
12:00-12:25
DANCEing with angioedema
12:25-12:30
Summary
12:30-13:30
Symposium
11:50-13:00
Problems you like, solutions you’re looking for –
An interactive patient journey
Facilitators: Karoline Krause (Germany) & Frank Siebenhaar (Germany)
13:30-14:20
Lunch Break
14:20-14:50
GA²LEN Session – GA²LEN General Assembly
Spotlight on Chronic Inducible Urticaria session
14:50-15:00
Cold Urticaria
15:00-15:10
Cholinergic Urticaria
15:10-15:20
Symptomatic dermographism
15:20-15:30
Solar Urticaria
Oral Presentation Session IV: Remission, Relapse, Disease modification, urticarial march – The nomenclature of CSU
15:30-16:06
Oral Presentations
Keynote lecture Session III: The Future of Urticariology
16:06-16:19
Unmet needs in research and management of urticaria
16:19-16:32
Best practice for patient management
16:32-16:45
Future Treatment Options for CU
16:45-17:05
Closing remarks / Prizes / Good byes
